Takeda Pharmaceutical (TAK) Long-Term Deferred Tax: 2018-2025

Historic Long-Term Deferred Tax for Takeda Pharmaceutical (TAK) over the last 8 years, with Mar 2025 value amounting to $2.4 billion.

  • Takeda Pharmaceutical's Long-Term Deferred Tax fell 8.57% to $2.4 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $2.4 billion, marking a year-over-year decrease of 8.57%. This contributed to the annual value of $2.4 billion for FY2025, which is 10.88% down from last year.
  • Per Takeda Pharmaceutical's latest filing, its Long-Term Deferred Tax stood at $2.4 billion for FY2025, which was down 10.88% from $2.7 billion recorded in FY2024.
  • Over the past 5 years, Takeda Pharmaceutical's Long-Term Deferred Tax peaked at $3.3 billion during FY2021, and registered a low of $2.4 billion during FY2025.
  • For the 3-year period, Takeda Pharmaceutical's Long-Term Deferred Tax averaged around $2.6 billion, with its median value being $2.7 billion (2023).
  • In the last 5 years, Takeda Pharmaceutical's Long-Term Deferred Tax grew by 17.73% in 2021 and then dropped by 16.10% in 2023.
  • Takeda Pharmaceutical's Long-Term Deferred Tax (Yearly) stood at $3.3 billion in 2021, then fell by 3.24% to $3.2 billion in 2022, then dropped by 16.10% to $2.7 billion in 2023, then increased by 0.81% to $2.7 billion in 2024, then fell by 10.88% to $2.4 billion in 2025.